



(1) Publication number:

0 442 448 A3

## (12)

### **EUROPEAN PATENT APPLICATION**

(21) Application number: 91101958.6

② Date of filing: 12.02.91

(a) Int. Cl.<sup>5</sup>: **C07D 207/327**, C07D 237/14, C07D 253/07, C07D 239/36, C07D 233/72, C07D 257/04, C07D 277/30, C07D 233/64, C07D 231/12, C07D 233/84, A61K 31/40

Priority: 13.02.90 US 479507

13.02.90 US 479508

13.02.90 US 479563

13.02.90 US 479561

13.02.90 US 479564

13.02.90 US 479559

13.02.90 US 479560

13.02.90 US 479506

20.06.90 US 540988

13.02.90 US 479505

(3) Date of publication of application:

21.08.91 Bulletin 91/34

Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

Date of deferred publication of the search report:

12.08.92 Bulletin 92/33

Applicant: Bristol-Myers Squibb Company 345 Park Avenue New York, N.Y. 10154(US)

Inventor: Meanwell, Nicholas
 Spice Hill Drive
 East Hampton, Connecticut 06424(US)

Representative: Kinzebach, Werner, Dr. et al Patentanwälte Reitstötter, Kinzebach und Partner Sternwartstrasse 4 Postfach 86 06 49 W-8000 München 86(DE)

Heterocyclic carboxylic acids and esters.

Heterocyclic acids and esters useful as inhibitors of mammalian blood platelet aggregation characterized by Formula I, II and VIII are disclosed.

$$HET_1 - (CH_2)_n CO_2 R \tag{I}$$

$$HET_2-CH_2CH_2 \longrightarrow OCH_2CO_2R_1$$
 (II)

$$\begin{array}{c|c} & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

#### EP 0 442 448 A3

Formula I compounds are those wherein n is 6-9, R is hydrogen, lower alkyl or an alkali metal ion, and HET<sub>1</sub> is heterocyclic radical selected from the group consisting of 3,4-diphenyl-1H-pyrrol-1-yl, 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl, 2,3-dihydro-3-oxo-5,6-diphenyl-1,2,4-triazin-2-yl, 1-oxo-4,5-diphenyl-2H-pyrimidin-1-yl, 2,5-dioxo-3,4-diphenylimidazolidin-1-yl, 5-(diphenylmethyl)-2H-tetrazol-2-yl, 4,5-diphenyl-2-thiazoyl, 4,5-diphenyl-1H-imidazol-2-yl, and 1,5-diphenyl-1H-pyrazol-3-yl.

Formula II compounds are those wherein R<sub>1</sub> is hydrogen, lower alkyl or an alkali metal ion, and the radical -OCH<sub>2</sub>CO<sub>2</sub>R is attached in the 3 or 4 ring position; and HET<sub>2</sub> is a heterocyclic radical selected from the group consisting of 4,5-diphenyl-2-thiazoyl, 4,5-diphenyl-1H-imidazol-2-yl,3,4-diphenyl-1H-pyrazol-1-yl, 4,5-diphenyl-1H-pyrazol-1-yl, 1-5-diphenyl-1H-pyrazol-3-yl, 1,6-dihydro-6-oxo-3,4-diphenyl-1-pyridazinyl, 2,3-dihydro-3-oxo-5,6-diphenylmethyl-1,2,3-triazin-2-yl, and 5-(diphenylmethyl)-2H-tetrazol-2-yl.

Formula VIII compounds are those wherein  $R_1$  is hydrogen, lower alkyl or an alkali metal ion, and the radical  $-OCH_2CO_2R$  is attached in the 3 or 4 ring position.

## **EUROPEAN SEARCH REPORT**

FD 91 10 1958

	DOCUMENTS CONS	IDERED TO BE RELE	VANT	EP 91 10 195 PAGE1
Category	Citation of document with indication, where appropriate, of relevant passages		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A,D	US-A-4 563 477 (F.S. M * claims 1,2 *		1,10,12	C070207/327 C070237/14 C070253/07
A,D	US-A-4 168 315 (R.H. R * claims 1,16 *	YNBRANDT ET AL.)	1,10,12	C070239/36 C070233/72 C070257/04
A,D	US-A-4 486 443 (A.G. C. * claims 1,14,16,33,44		1,10,12	C070277/30 C070233/64 C070231/12
<b>A</b>	EP-A-0 054 593 (SANOFI * claims 1,3 *	, S.A.) 	1,10,12	C07D233/84 A61K31/40 A61K31/41
A,D	US-A-4 330 550 (HH. * column 3, line 49 -	LAUTENSCHLÄGER ET AL.) line 59; claim 1 *	1,12	A61K31/415 A61K31/425 A61K31/50
A	EP-A-0 143 461 (KAKEN   * abstract; claim 1 *	PHARMACEUTICAL CO., LTD.	) 1,12	
A,D	US-A-4 460 598 (HH.   * claims 1,21 *	LAUTENSCHLÄGER ET AL.)	1,10	TECHNICAL FIELDS
A,D	US-A-4 677 105 (G. PITE * claims 1,3 *	ET <b>ET AL</b> .) 	1,10	SEARCHED (Int. Cl.5)
A,D	US-A-4 826 868 (M.P. W	ACHTER ET AL.)	1,10	
A, D	US-A-2 712 542 (J.A. K. * column 3, line 8 - 1	•	1,10	
A,D	US-A-3 453 285 (S. HAY/ * abstract; claim 1 *	AO ET AL.)	1,10	
A,D	US-A-3 506 679 (J.F. C. * abstract; claim 1 *	AVALLA ET AL.)	1,10	
A,D	US-A-4 853 404 (N. TAKA * claims 1,10 *	AMURA ET AL.)	2,10	
		-/		
	The present search report has b	ocen drawn up for all claims	·	
Place of search Date of completion of the			Knawiner	
X : part Y : part docu	ERLIN  CATEGORY OF CITED DOCUME  cularly relevant if taken alone  cularly relevant if combined with an  ment of the same category  nological background	E : earlier p after the other D : documer L : documer	r principle underlying the atent document, but publi filing date nt cited in the application at cited for other reasons	invention shed on, or
O: non-	written disclosure mediate document		of the same patent family	



# **EUROPEAN SEARCH REPORT**

Application Number

EP 91 10 1958 PAGE2

Category	Citation of document with indic of relevant passag	ation, where appropriate, ges	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)	
A	US-A-4 734 421 (M.L. HAPPK * example 7 *	ONO ET AL.)	3		
				<i>,</i> ,	
		·			
				TECHNICAL FIELDS	
				SEARCHED (Int. Cl.5)	
		•			
ļ					
1	The present search report has been	drawn up for all claims			
Place of search		Date of completion of the search		Exercises	
	BERLIN	10 JUNE 1992		istian Hass	
CATEGORY OF CITED DOCUMENTS  X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure		T : theory or princ E : earlier patent of after the filing D : document cites L : document cites	T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filling date D: document cited in the application L: document cited for other reasons		
O : non-written disclosure P : intermediate document		&: member of the document	<ul> <li>a: member of the same patent family, corresponding document</li> </ul>		